{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 416967709
| IUPAC_name = (''RS'')-5-[(2- cyclopropyl-7,8-dimethoxy-2''H''-chromen-5-yl)methyl]pyrimidine-2,4-diamine
| image = Iclaprim2DACS.svg
| width = 250px
| chirality = [[Racemic mixture]]
| drug_name = 
<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Investigational
| routes_of_administration = intravenous

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 192314-93-5
| ATC_prefix = J01
| ATC_suffix = EA03
| PubChem = 213043
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 42445HUU0O
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08337
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 131724
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 134561
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 184736
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = HWJPWWYTGBZDEG-UHFFFAOYSA-N

<!--Chemical data-->
| C=19 | H=22 | N=4 | O=3 
| molecular_weight = 354.403 g/mol
| smiles = COC1=C(C2=C(C=CC(O2)C3CC3)C(=C1)CC4=CN=C(N=C4N)N)OC
}}

'''Iclaprim''' is an [[antibiotic]] drug candidate that is active against [[gram positive organisms]].<ref>{{cite journal|last1=Barton|first1=E|last2=MacGowan|first2=A|title=Future treatment options for Gram-positive infections--looking ahead.|journal=Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases|date=December 2009|volume=15 Suppl 6|pages=17-25|pmid=19917023|url=http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)60660-1/fulltext}}</ref><ref name=Abbas2017rev>{{cite journal|last1=Abbas|first1=M|last2=Paul|first2=M|last3=Huttner|first3=A|title=New and improved? A review of novel antibiotics for Gram-positive bacteria.|journal=Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases|date=19 June 2017|doi=10.1016/j.cmi.2017.06.010|pmid=28642145}}</ref> It is administered intravenously.<ref>{{cite web|title=Iclaprim for the Treatment of Complicated Skin and Skin Structure Infections|url=https://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b3-01-FDA.pdf|publisher=FDA|date=November 20, 2008}}</ref>{{rp|3}}

''[[In vitro]]'', iclaprim is active against [[methicillin-resistant Staphylococcus aureus]] (MRSA), [[vancomycin-resistant Staphylococcus aureus|vancomycin-resistant ''Staphylococcus aureus'']] (VRSA), strains of ''[[Streptococcus pneumoniae]]'' resistant to several common antibiotics, and some [[gram-negative bacteria]].<ref name=Kohlhoff>{{cite journal|last=Kohlhoff|first=SA|author2=Sharma, R|title=Iclaprim.|journal=Expert Opinion on Investigational Drugs|date=September 2007|volume=16|issue=9|pages=1441–8|doi=10.1517/13543784.16.9.1441|pmid=17714029}}</ref> It is of the [[diaminopyrimidine]] [[dihydrofolate reductase]] (DHFR)-[[enzyme inhibitor|inhibiting]] type.

==History==
Iclaprim is an optimized analog of [[trimethoprim]] that was discovered by scientists at [[Hoffmann-La Roche|Roche]].<ref name=FT/> Arpida was spun out of Roche in 1998<ref name=FT>{{cite news|last1=Firn|first1=David|title=Arpida takes advice on stock market flotation|url=http://www.ft.com/cms/s/0/ba106f40-1b21-11d9-9fe4-00000e2511c8.html?ft_site=falcon&desktop=true#axzz4sXEJEPfM|work=Financial Times|date=11 October 2004}}</ref><ref name=Silver>{{cite journal|last1=Silver|first1=LL|title=Challenges of antibacterial discovery.|journal=Clinical microbiology reviews|date=January 2011|volume=24|issue=1|pages=71-109|doi=10.1128/CMR.00030-10|pmid=21233508|pmc=3021209}}</ref> and acquired iclaprim from Roche in 2001.<ref name=F1/>{{rp|77}} Arpida held an IPO on the Swiss stock exchange in 2005.<ref>{{cite news|last1=Thompson|first1=Valerie|title=Roche spin-off plans float to fund drug trials|url=https://www.swissinfo.ch/eng/roche-spin-off-plans-float-to-fund-drug-trials/4453828|work=SWI swissinfo.ch|date=April 12, 2005|language=en}}</ref> 

Arpida ran two Phase III clinical trials for complicated [[skin and skin structure infection]]s, called ASSIST 1 and 2, that were completed by 2008 but as of 2017 had not been published in the [[medical literature]].<ref name=Abbas2017rev/>   A [[new drug application]] was filed with the FDA bssed on these trials and was rejected due to failure to show non-inferiority and due to safety concerns, especially [[drug-induced QT prolongation]].<ref name=Abbas2017rev/><ref name=FDAdocs2008>{{Cite web|url=https://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4394m3--final%2020%20Nov.pdf|title=Summary Minutes of the Anti-Infective Drugs Advisory Committee November 18-20, 2008|last=|first=|date=|website=US Food and Drug Administration|archive-url=|archive-date=|dead-url=|access-date=}}. {{Cite web|url=https://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b3-01-FDA.pdf|title=Iclaprim for the Treatment of Complicated Skin and Skin Structure Infections FDA Briefing Document for Anti-Infective Drugs Advisory Committee Meeting|last=|first=|date=20 November 2008|website=US Food and Drug Administration}}</ref> The FDA advisory committee said that the drug "should not be developed further" based on the results presented.<ref name=InPharma2015>{{cite news|last1=King|first1=Anthony|title=FDA veteran questions science behind antibiotics fast track|url=http://www.in-pharmatechnologist.com/Regulatory-Safety/FDA-veteran-questions-science-behind-antibiotics-fast-track|work=In-PharmaTechnologist|date=3 August 2015}}</ref> A parallel application for marketing approval to the EMA was withdrawn in 2009; in the announcement of the withdrawal, the EMA said that there was insufficient data from clinical studies to justify the dosage proposed by the company and that resistance to the drug had already been seen in the clinical trial data.<ref name=EMA>{{cite news|title=Questions and answers on the withdrawal of the marketing authorisation application for Mersarex (iclaprim)|url=http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/01/WC500060215.pdf|work=EMA|date=19 November 2009}}</ref> 

Arpida collapsed after the rejection by the FDA and the EMA withdrawal.<ref name=Silver/> Arpida and the privately owned Swiss company Evolva began discussing an acquisition of Arpida by Evolva, which would allow Evolva to go public via a [[reverse merger]] in September 2009.<ref>{{cite news|title=Privately owned Evolva takes over biotech Arpida|url=http://www.reuters.com/article/us-arpida/privately-owned-evolva-takes-over-biotech-arpida-idUSTRE58917E20090910|work=Reuters|date=September 10, 2009}}</ref> Arpida sold off iclaprim to Acino Pharma in November 2009,<ref>{{cite news|title=Press Release: Acino Acquires Iclaprim Activities from Arpida|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=200551|work=Acino, Roche, Arpida  via Evaluate Group|date=November 4, 2009}}</ref> and in December 2009 Arpida and Evolva completed their transaction.<ref>{{cite news|title=Press Release: Evolva SA Completes Merger With Arpida Ltd|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=202415&sectionID=&isEPVantage=no|work=Evolva Holding, Novartis, Arpida via Evaluate Group|date=December 14, 2009}}</ref>

Acino sold the rights to iclaprim, its data and regulatory filings, and manufactured drug to a group called Life Sciences Management Group, Inc. of Bethesda, Maryland, in September 2013 and that company assigned its rights to a company called Nuprim,<ref name=F1>{{cite web|title=Form F-1|url=https://www.sec.gov/Archives/edgar/data/1674657/000104746916014288/a2229010zf-1.htm|publisher=Motif Bio plc via SEC Edgar|date=July 12, 2016}}</ref>{{rp|F-32}} which had been formed by the former CEO, CSO, and US agent of Arpida in 2014.<ref>{{cite web|title=Press release: Motif Bio Announces Intention to Float on AIM|url=https://www.motifbio.com/news/motif-bio-announces-intention-to-float-on-aim/|publisher=Motif Bio plc|date=February 2, 2015|archiveurl=https://web.archive.org/web/20160317221147/https://www.motifbio.com/news/motif-bio-announces-intention-to-float-on-aim/|archivedate=17 March 2016}}</ref> In December 2014 Motif BioSciences Inc. and Nuprim signed an agreement allowing Motif to acquire the iclaprim assets, and the transaction was completed in April 2015.<ref name=F1/>{{rp|iv}}  In 2015 the FDA granted [[qualified infectious disease product]] status for iclaprim.<ref name=InPharma2015/>

As of 2017 iclaprim was in two Phase III trials to show non-inferiority to [[vancomycin]] in acute skin and skin structure infection called REVIVE 1 and 2.<ref name=Abbas2017rev/>  In September 2017 the FDA granted orphan drug status to iclaprim for the treatment of staphylococcus aureus lung infections in people with cystic fibrosis.<ref>{{cite web|title=Iclaprim Orphan Drug Designation|url=https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=514415|publisher=FDA|accessdate=16 September 2017}}</ref>

==Names==
During its development other names for the drug have included AR-100, MTF-100, RO-48-2622,<ref>{{cite web|title=Iclaprim|url=http://adisinsight.springer.com/drugs/800018080|publisher=AdisInsight|accessdate=13 September 2017|language=en}}</ref> and the brand name Mersarex.<ref name=EMA/> It received its INN name in 2003.<ref>{{cite journal|title=Recommended INN List 50|journal=WHO Drug Information|date=2003|volume=17|issue=4|url=http://www.who.int/medicines/publications/druginformation/innlists/RL50.pdf?ua=1}}</ref>

==References==
{{reflist}}

==External links==
* [https://www.sps.nhs.uk/medicines/iclaprim/ Iclaprim at UK Speciality Pharma Service]

==Further reading==
*{{cite journal |vauthors=Schneider P, Hawser S, Islam K |title=Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria |journal=Bioorg Med Chem Lett |volume=13 |issue=23 |pages=4217–21 |date=December 2003 |pmid=14623005 |doi= 10.1016/j.bmcl.2003.07.023|url=}}
{{Clear}}

{{Sulfonamides and trimethoprim}}

[[Category:Bacterial dihydrofolate reductase inhibitors]]
[[Category:Pyrimidines]]
[[Category:Chromenes]]
[[Category:Phenol ethers]]
[[Category:Cyclopropanes]]
[[Category:Aromatic amines]]
[[Category:Experimental drugs]]